Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
The closing price of Transmedics Group Inc (NASDAQ: TMDX) was $67.03 for the day, up 9.75% from the previous closing price of $61.07. In other words, the price has increased by $9.75 from its previous closing price. On the day, 1.77 million shares were traded. TMDX stock price reached its highest trading level at $67.0999 during the session, while it also had its lowest trading level at $60.46.
Ratios:
Our analysis of TMDX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 7.33 and its Current Ratio is at 8.20. In the meantime, Its Debt-to-Equity ratio is 2.47 whereas as Long-Term Debt/Eq ratio is at 2.46.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, JP Morgan on December 17, 2024, Downgraded its rating to Neutral and sets its target price to $75 from $116 previously.
Oppenheimer reiterated its Outperform rating for the stock on October 29, 2024, while the target price for the stock was revised from $200 to $125.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jan 07 ’25 when Khayal Tamer I sold 1,083 shares for $80.05 per share. The transaction valued at 86,694 led to the insider holds 20,843 shares of the business.
Khayal Tamer I sold 1,084 shares of TMDX for $93,658 on Dec 02 ’24. The Chief Commercial Officer now owns 20,843 shares after completing the transaction at $86.40 per share. On Nov 11 ’24, another insider, Khayal Tamer I, who serves as the Chief Commercial Officer of the company, sold 1,458 shares for $90.04 each. As a result, the insider received 131,278 and left with 20,843 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TMDX now has a Market Capitalization of 2249459712 and an Enterprise Value of 2437512704. As of this moment, Transmedics’s Price-to-Earnings (P/E) ratio for their current fiscal year is 71.81, and their Forward P/E ratio for the next fiscal year is 45.62. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.61 while its Price-to-Book (P/B) ratio in mrq is 10.72. Its current Enterprise Value per Revenue stands at 6.077 whereas that against EBITDA is 47.665.
Stock Price History:
The Beta on a monthly basis for TMDX is 2.10, which has changed by -0.28797948 over the last 52 weeks, in comparison to a change of 0.25219524 over the same period for the S&P500. Over the past 52 weeks, TMDX has reached a high of $177.37, while it has fallen to a 52-week low of $55.00. The 50-Day Moving Average of the stock is -3.67%, while the 200-Day Moving Average is calculated to be -43.72%.
Shares Statistics:
TMDX traded an average of 2.32M shares per day over the past three months and 2513140 shares per day over the past ten days. A total of 33.56M shares are outstanding, with a floating share count of 32.43M. Insiders hold about 3.39% of the company’s shares, while institutions hold 109.92% stake in the company. Shares short for TMDX as of 1736899200 were 8990700 with a Short Ratio of 3.87, compared to 1734048000 on 8639718. Therefore, it implies a Short% of Shares Outstanding of 8990700 and a Short% of Float of 32.580003000000005.
